- Home
- AESI vs ORKA Comparison
AESI vs ORKA Comparison
Compare AESI & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AESI | ORKA |
|---|---|---|
| Founded | 2017 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | AESI | ORKA |
|---|---|---|
| Price | $9.88 | $30.94 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 9 |
| Target Price | $16.39 | ★ $45.22 |
| AVG Volume (30 Days) | ★ 3.1M | 403.7K |
| Earning Date | 11-03-2025 | 11-12-2025 |
| Dividend Yield | ★ 9.95% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,117,218,000.00 | N/A |
| Revenue This Year | $4.55 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 20.68 | N/A |
| 52 Week Low | $7.64 | $5.49 |
| 52 Week High | $26.86 | $31.80 |
Technical Indicators
Market Signals| Indicator | AESI | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 53.85 | 62.41 |
| Support Level | $7.64 | $26.73 |
| Resistance Level | $9.40 | $31.00 |
| Average True Range (ATR) | 0.52 | 1.82 |
| MACD | 0.22 | 0.01 |
| Stochastic Oscillator | 85.46 | 84.30 |
Price Performance
Historical ComparisonAbout AESI Atlas Energy Solutions Inc.
Atlas Energy Solutions Inc is a provider of proppant and logistics services to the oil and natural gas industry within the Permian Basin of West Texas and New Mexico, the most active oil and natural gas basin in North America. Proppant is necessary to facilitate the recovery of hydrocarbons from oil and natural gas wells. One hundred percent of its sand reserves are located in Winkler and Ward Counties, Texas, within the Permian Basin, and its operations consist of proppant production and processing facilities, including two facilities near Kermit, Texas, and a third facility near Monahans, Texas.
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.